AstraZeneca: Calquence approved in China

(CercleFinance.com) - AstraZeneca announces that Calquence (acalabrutinib) has been conditionally approved in China for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.


This is the first approved indication for Calquence in China.

The conditional approval by the National Medical Products Administration (NMPA) is based on positive results from two clinical trials.


Copyright (c) 2023 CercleFinance.com. All rights reserved.